CN101291650B - 抗炎组合物及其使用方法 - Google Patents
抗炎组合物及其使用方法 Download PDFInfo
- Publication number
- CN101291650B CN101291650B CN2005800518433A CN200580051843A CN101291650B CN 101291650 B CN101291650 B CN 101291650B CN 2005800518433 A CN2005800518433 A CN 2005800518433A CN 200580051843 A CN200580051843 A CN 200580051843A CN 101291650 B CN101291650 B CN 101291650B
- Authority
- CN
- China
- Prior art keywords
- compositions
- antiinflammatory
- mass percent
- product
- personal care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title abstract description 13
- 244000192528 Chrysanthemum parthenium Species 0.000 claims abstract description 17
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 17
- 235000008384 feverfew Nutrition 0.000 claims abstract description 17
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 16
- 235000001014 amino acid Nutrition 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims abstract description 9
- 240000007817 Olea europaea Species 0.000 claims description 35
- 239000000284 extract Substances 0.000 claims description 32
- 235000002725 Olea europaea Nutrition 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 8
- 229930003799 tocopherol Natural products 0.000 claims description 7
- 239000011732 tocopherol Substances 0.000 claims description 7
- 239000006286 aqueous extract Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 235000010384 tocopherol Nutrition 0.000 claims description 5
- 229960001295 tocopherol Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- 229940083542 sodium Drugs 0.000 claims description 4
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 claims description 3
- 229960001983 magnesium aspartate Drugs 0.000 claims description 3
- 229940068988 potassium aspartate Drugs 0.000 claims description 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims description 2
- 235000019149 tocopherols Nutrition 0.000 claims description 2
- 229930003802 tocotrienol Natural products 0.000 claims description 2
- 239000011731 tocotrienol Substances 0.000 claims description 2
- 235000019148 tocotrienols Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- CRSJYWPXKKSOCQ-CBAPHJFVSA-L magnesium;(2s)-2-aminobutanedioate;hydron;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O CRSJYWPXKKSOCQ-CBAPHJFVSA-L 0.000 claims 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 3
- 239000002184 metal Substances 0.000 abstract description 3
- 229940114496 olive leaf extract Drugs 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 3
- 244000306301 Caesalpinia sappan Species 0.000 abstract description 2
- 235000015162 Caesalpinia sappan Nutrition 0.000 abstract description 2
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 abstract 1
- 235000002294 Ilex volkensiana Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 32
- 210000003491 skin Anatomy 0.000 description 26
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 17
- 210000002540 macrophage Anatomy 0.000 description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 230000003213 activating effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 241000717739 Boswellia sacra Species 0.000 description 9
- 239000004863 Frankincense Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- -1 ascorbic acid glucoside Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 206010038419 Renal colic Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241001077909 Sigesbeckia Species 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 241000893966 Trichophyton verrucosum Species 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000005282 brightening Methods 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 2
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical class OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- ZZHNYTLKRMBVAI-NLPXPOPTSA-N (8r,9s,10r,13s,14s)-13-(hydroxymethyl)-10-methyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical class C([C@]1(CO)C(=O)CC[C@H]1[C@@H]1CC2)C[C@@H]1[C@]1(C)C2=CC(=O)CC1 ZZHNYTLKRMBVAI-NLPXPOPTSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241001044369 Amphion Species 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 241001608538 Boswellia Species 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- GXABJFOLOHUYJT-UHFFFAOYSA-N [S].OC1=CC=CC(O)=C1 Chemical compound [S].OC1=CC=CC(O)=C1 GXABJFOLOHUYJT-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001055 reflectance spectroscopy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
提供了抗炎组合物，其包含(a)抗炎剂，选自橄榄叶提取物、豨莶草、苏木、野甘菊以及其中两种或多种的组合；和(b)抗炎剂，其包含至少一种亲脂性氨基酸和至少一种金属盐。还提供了包含所述组合物的个人护理产品及其使用方法。
Description
发明领域
本发明涉及具有抗炎特性的组合物，更具体地涉及包含抗炎剂的组合的组合物，与常规组合物相比，该组合物具有意想不到高的协同抗炎特性。
背景技术
已知许多适用于个人护理组合物的皮肤护理活性剂。这些皮肤护理活性剂的例子包括橄榄叶提取物，已知这些提取物具有降血压和降血糖活性、用于食物和化妆品中具有清除自由基的特性，口服途径给予时则显示抗炎活性(例如，参见“富含橄榄苦甙的洋橄榄叶提取物、其产品、以及含有其成分的药物和组合物的应用”，Combes，Georges；Escaut，Alexandre.法国专利申请，FR 2507477 A119821217，1982；Gonzalez M等，“橄榄叶的降血糖活性”，Planta Med 1992Dec；58(6)：513-515；洋橄榄叶提取物作为抗自由基剂的应用”，Amari，Giorgio.欧洲专利申请(1999)，EP 937455 A1 19990825；Fehri B等“洋橄榄：刺激剂、抗溃疡和抗炎症作用”，Boll Chim Farm(1996)135(1)：42-49)；豨莶(Sigesbeckia，豨莶草)，用作疟疾、风湿病、肾绞痛的治疗，以及与甘油联用来治疗癣菌病；苏木(Lignum Sappan，苏木)，用于促进血循环和化淤，消肿和镇痛；以及野甘菊，认为其用作一般退热剂，口服后具有显著的医疗效果。其它皮肤护理活性剂包括：油性提取物，例如乳香(Boswellia Serrata)油提取物(乳香)，具有抗肿瘤和抗关节炎活性；和燕麦油提取物，具有抗刺激和抗氧化活性。
申请人认识到，需要开发皮肤护理活性剂的组合，以有效治疗、缓解和/或预防各种原因导致的皮肤炎症。虽然申请人认识到许多活性剂具有抗炎特性，但是通常难以(甚至是不可能)预测这些活性剂的组合在缓解炎症方面将具有意想不到高的协同抗炎特性和有效性。
此外，申请人还认识到，从成本考虑在某些应用中希望使用相对少量的活性剂，而出于稳定性的原因则希望减少与某些活性剂有关的不良颜色或气味。然而，许多活性剂或其组合以相对低的含量应用时，在缓解炎症方面几乎没有或没有效果。因此，申请人认识到，需要具有相对高的协同抗炎特性和有效性的皮肤护理活性剂的组合，某些组合甚至在相对低的含量下同样有效。
发明概述
申请人发现了组合物，该组合物符合皮肤护理活性剂的组合应具有意想不到高的协同抗炎特性的突出需要。此外，申请人认识到，某些组合物在相对低的含量时意外地具有高抗炎特性。
根据某些实施方式，本发明提供了组合物，该组合物包含(a)抗炎剂，选自橄榄叶提取物、豨莶草、苏木、野甘菊以及它们中的两种或多种的组合；和(b)抗炎剂，包含至少一种脂氨基酸和至少一种金属盐。
根据另一些实施方式，本发明提供了包含本发明组合物的个人护理产品。
在又一些实施方式中，本发明提供了治疗/缓解炎症和/或发红的方法，该方法包括使需要缓解炎症的皮肤与本发明组合物接触，和/或使需要缓解炎症的皮肤与本发明个人护理产品接触。
具体实施方式
根据某些优选的实施方式，本发明提供了包含以下成分的组合物：(a)抗炎剂，包括橄榄叶提取物、豨莶草、苏木、野甘菊或它们中的两种或多种的组合；和(b)抗炎剂，包含至少一种脂氨基酸或其盐和至少一种金属盐。申请人意外地发现，这些抗炎剂的组合具有协同作用和意想不到高的抗炎特性，具体地说，本发明组合物的抗炎特性要高于各个活性成分的抗炎特性之和，常常高约1.2倍到约1.8倍。
如本文所用，术语“抗炎剂”通常是指引入患炎症的皮肤后能够缓解炎症的任意化合物或化合物的组合。适用于本发明的活性剂的例子包括橄榄叶提取物，包括任何水溶性和油溶性洋橄榄(Olea europea)提取物，以及豨莶草、苏木、野甘菊，它们中的两种或多种的组合，等等。在某些优选的实施方式中，活性剂包括橄榄叶提取物。许多合适的活性剂可从一种或多种来源商业购得，例如橄榄叶提取物(意大利米兰的B&T srl公司有售商品名为Eurol BT的水溶性提取物，和Active Organics公司有售油溶性提取物)，豨莶草(Sederma Edison NJ公司有售)和野甘菊(意大利米兰的Indena公司有售)，等等。
这里可使用任何合适的化妆品学上可接受的抗炎剂，其包含至少一种脂氨基酸和至少一种金属盐。合适的脂氨基酸的例子包括：将氨基酸(例如丙氨酸、甘氨酸、谷氨酸、天冬氨酸等)连接至脂肪酸链(例如椰油基链或其它链)形成的物质及其衍生的盐。某些优选的脂氨基酸包括：椰油基氨基酸(将丙氨酸、甘氨酸、谷氨酸和天冬氨酸连接至椰油基部分形成)及其盐，包括钠盐、钾盐等。某些尤其优选的脂氨基酸包括椰油基氨基酸钠。合适的金属盐的例子包括钠盐、钾盐、钙盐、镁盐、其中两种或多种的组合等。某些优选的金属盐包括天冬氨酸盐、葡糖酸盐、葡萄糖磷酸盐等。某些优选的抗炎剂包含至少一种脂氨基酸和至少一种金属天冬氨酸盐。某些更优选的试剂包含一种或多种脂氨基酸以及至少两种金属天冬氨酸盐。例如，一种尤其优选的抗炎剂包含椰油基氨基酸钠、天冬氨酸镁和天冬氨酸钾的组合(与肌氨酸组合)，Seppic公司有售，商品名为赛普康姆S(Sepicalm S)和赛普康姆S WP(Sepicalm S WP)购得。
本发明中可使用任何合适的量的(a)抗炎剂，选自橄榄叶提取物、豨莶草、苏木、野甘菊以及它们中的两种或多种的组合(“试剂(a)”)；和(b)抗炎剂，包含至少一种脂氨基酸和至少一种金属盐(“试剂(b)”)。在某些实施方式中，本发明组合物包含质量百分比0-100％的试剂(a)和质量百分比100-0％的试剂(b)(如本文所用，除非另有说明，术语“质量百分比”表示活性剂占试剂(a)和试剂(b)的总重量的质量百分比)。在某些优选的实施方式中，组合物包含质量百分比约10-90％的试剂(a)和质量百分比约90-10％的试剂(b)，更优选质量百分比约20-80％的试剂(a)和质量百分比约80-20％的试剂(b)，甚至更优选质量百分比约40-60％的试剂(a)和质量百分比约60-40％的试剂(b)。
在某些优选的实施方式中，试剂(a)与试剂(b)的重量比为约4∶1到约1∶4。在某些其它优选的实施方式中，该比例为约2∶1到约1∶2，在另一些实施方式中，优选为约1∶1。
除了试剂(a)和试剂(b)外，本发明组合物可还包含任意其它类型的抗炎剂和其它化妆品活性剂。“化妆品活性剂”是指对皮肤具有美容或治疗效果的化合物，例如治疗皱纹、痤疮或亮化皮肤的试剂。在一个实施方式中，该试剂选自下组，包括但不限于：羟酸；过氧苯甲酰；硫间苯二酚；D-泛醇；氢醌；抗炎剂；皮肤亮化剂；抗微生物剂和抗真菌剂，如咪康唑、酮康唑、elubial；维生素，例如抗坏血酸；生育酚和生育三烯酚，例如醋酸生育酚；类视黄醇，例如视黄醇、视黄醛、视黄醇棕榈酸酯、视黄醇乙酸酯和视黄酸；激素，例如雌激素和二羟雄烯二酮；2-二甲基氨基乙醇；硫辛酸；氨基酸，例如脯氨酸和酪氨酸；乳糖酸；自晒黑试剂，例如二羟丙酮；二甲基氨基乙醇；乙酰辅酶A；烟酸；核黄素；硫胺素；核糖；电子运载体，例如NADH和FADH2；植物提取物，例如银杏、芦荟和大豆提取物；以及它们的衍生物。羟酸的例子包括但不限于：(i)α-羟基酸，例如羟乙酸、乳酸、苹果酸、柠檬酸和酒石酸，(ii)β-羟基酸，例如水杨酸，和/或(iii)多羟基酸。例如参见欧洲专利申请第273,202号。抗坏血酸衍生物的例子包括但不限于：抗坏血酸棕榈酸盐、抗坏血酸磷酸镁、抗坏血酸磷酸钠、抗坏血酸磷酸锌、抗坏血酸葡糖苷、抗坏血酸钠和抗坏血酸多肽。氢醌衍生物的例子包括但不限于：熊果苷。在某些优选的实施方式中，本发明的组合还包含一种或多种生育酚和/或生育酚酯，例如醋酸生育酚。
申请人已认识到，将本发明具有意想不到高抗炎活性的组合物用于任意一种个人/健康护理产品中，具有极大的优点。例如，本发明组合物可用于乳霜、乳液、香油、洗涤剂、凝胶、棒、喷雾、软膏、摩丝和化妆品/彩妆中。这些产品可包含几种类型的化妆品学上可接受的载体系统，包括但不限于单相溶液(例如，油基溶液)、乳剂和凝胶。术语“化妆品学上可接受的局部施用载体”是指其中分散或溶解有其它成分且具有可接受的安全性的局部施用载体。个人护理产品可用于皮肤护理、婴儿护理、妇女健康、伤口护理、其中两种或多种的组合等等。这些产品可根据其多种优点中的任一种进行推广，包括尿布湿疹降低、抗痤疮、抗老化、UV保护、舒缓、保湿、其中两种或多种作用的组合，等等。
包含本发明试剂组合物的个人/健康护理产品可还包含任一种个人护理产品中常用的材料。例如，可使用一种或多种阴离子、非离子、两性离子和/或阳离子表面活性剂，珠光剂或遮光剂，增稠剂，次级调理剂，湿润剂，螯合剂，改进组合物的外观、触感和香味的添加剂，例如着色剂、芳香剂、防腐剂、pH调节剂等。
根据本发明制备的个人护理产品可包含任何合适的量的本发明抗炎组合物。申请人意外地发现，本发明组合物具有显著的抗炎效果，即使在个人护理制剂中存在的量相对较低，例如以个人护理产品的总重量计算(后文中称为“产品中组合物的质量百分比”)，活性剂的质量百分比低到约0.02％或更低。因此，本发明个人护理产品可包含质量百分比约0-5％的组合物，包括质量百分比约0.02-4％、质量百分比约0.1-2％、质量百分比约0.1-1％的组合物。在某些优选的实施方式中，个人护理产品包含产品质量百分比约0-1％的组合物，更优选产品质量百分比约0.02-0.5％，甚至更优选产品质量百分比约0.02-0.1％的组合物。
本发明还提供了治疗和/或缓解任何原因导致的皮肤炎症和/或发红的方法，所述原因包括但不限于，各种形式的湿疹和银屑病，痤疮和红斑痤疮，接触刺激和过敏性皮炎，阳光诱导的皮肤病，外来生物体导致的感染，虫咬，物理擦伤和皮肤干燥。在某些实施方式中，该方法包括：使需要抗炎治疗的皮肤与上述本发明组合物相接触。在某些优选的实施方式中，本发明方法包括使皮肤与包含以下成分的组合物相接触，所述组合物包含抗炎剂，选自橄榄叶提取物、豨莶草、苏木、野甘菊及其两种或多种的组合；以及含有至少一种脂氨基酸和至少一种金属盐的试剂。在某些其它实施方式中，本发明提供了治疗和/或缓解皮肤炎症的方法，该方法包括使需要抗炎治疗的皮肤与包含本发明组合物的个人护理产品相接触。
根据本发明方法，本发明组合物和/或个人护理产品可通过多种方式与皮肤接触。例如，组合物和产品可局部施加到皮肤、毛发或指甲上。优选地，在某些实施方式中，组合物和/或产品局部施加到皮肤上。
申请人发现，本发明方法能够缓解皮肤发红，而且通常能以比类似方法更有效的方式缓解皮肤炎症。
实施例
以下实施例进一步阐述本发明，这些实施例是示例性而非限制性的。
实施例1：对RAW 264巨噬细胞株的评价
大量皮肤中发现的单核吞噬细胞或巨噬细胞是天然免疫反应的重要组成部分。皮肤中，巨噬细胞通过产生一种强效促炎介质——一氧化氮，主要参与外来病原体如细菌的识别与消除。然而，一氧化氮的释放也可导致皮肤炎症并引起相邻皮肤细胞损伤，不受调节的一氧化氮产生可导致组织损伤。以下试验中，橄榄叶提取物、赛普康姆、或橄榄叶提取物与赛普康姆的组合，能通过减少巨噬细胞的活化，从而能影响炎症反应。
将鼠巨噬细胞株(RAW264)细胞在含10％FBS的DMEM(美国标准生物品收藏中心，Manassas，VA)中调节至4×1056个细胞/毫升的密度，然后以100μL加入到平底96-孔组织培养板中。用1μg/ml的细菌细胞壁组分脂多糖(LPS)刺激鼠巨噬细胞，作为阳性对照；或者用或不用橄榄叶提取物、赛普康姆或橄榄叶提取物和赛普康姆的组合来刺激细胞。在37℃、5％ CO2条件下，用或者不用试验样品处理巨噬细胞培养物24小时，然后形成亚硝酸盐，用Griess分析测定稳定的一氧化氮最终产物。结果表示为与刺激的对照培养物相比，炎症介质产生的抑制百分比。
LPS刺激的RAW 264鼠巨噬细胞
| 试验物质(浓度) | 一氧化氮释放的抑制百分比(％) | 赛普康姆∶橄榄叶提取物的比例 |
| 橄榄叶提取物(.01％)赛普康姆(.01％)橄榄叶提取物(.01％)+赛普康姆(.01％) | 6.5+/-0.812.1+/-0.0520.9+/-0.02* | 1∶1 |
| 橄榄叶提取物(.02％)赛普康姆(.02％)橄榄叶提取物(.02％)+赛普康姆(.02％) | 24.5+/-1.227.1+/-1.177.2+/-0.1＊ | 1∶1 |
| 橄榄叶(.005％)赛普康姆(.02％)橄榄叶(.005％)+赛普康姆(.02％) | 1.31+/-0.632.1+/-0.639.8+/-1.4＊ | 4∶1 |
| 赛普康姆(.005％)橄榄叶(.02％)赛普康姆(.005％)+橄榄叶(.02％) | 3.26+/-1.516.6+/-0.629.31+/-2.1＊ | 1∶4 |
*采用不配对students’t检验，与单独使用橄榄叶提取物或赛普康姆相比P＜0.05。
虽然橄榄叶提取物和赛普康姆各自具有中等抗炎活性，我们意外地发现，橄榄叶提取物与赛普康姆的组合能非常有效地缓解炎症。橄榄叶提取物与赛普康姆组合的抗炎活性大于其各自活性之和，表明橄榄叶提取物与赛普康姆的组合具有协同作用。
实施例2：在RAW 264巨噬细胞株中赛普康姆对水溶性与油溶性天然提取物的强化作用比较
以下试验中赛普康姆能够降低巨噬细胞的活性，表明其能协同增强天然物质的水溶性和油溶性提取物的抗炎症能力。
将鼠巨噬细胞株(RAW264)细胞在含10％FBS的DMEM(美国标准生物品收藏中心，Manassas，VA)中调节至4×1056个细胞/毫升的密度，然后以100μL加入到平底96-孔组织培养板中。用0.1μg/ml的细菌细胞壁组分脂多糖(LPS)刺激鼠巨噬细胞，作为阳性对照；或者用或不用赛普康姆、水溶性提取物(豨莶(Siegesbeckia)和苏木(Lignum Sappan))、部分水溶性/部分油溶性提取物(野甘菊)、油溶性提取物(燕麦油提取物，乳香油提取物)、或提取物与赛普康姆的组合来刺激细胞。豨莶，也称为豨莶草，是一种水性提取物(Sederma Edison NJ)。在中国常用它来治疗疟疾、风湿病和肾绞痛；在英国则主要与甘油联用治疗癣菌病。苏木是一种苏木(Caesalpinia sappan)干燥心材的水性提取物。它可用来促进血循环和化淤，用于消肿和镇痛。野甘菊同时具有水溶性和油溶性组分(Indena公司，意大利米兰)。解热菊(Tanacetum parthenium)是一种通常称为野甘菊的植物，自中世纪已认识到其作为一般退热剂使用，口服后具有显著的医疗效果，因而得名。乳香油提取物(Quest Intl，South Plainfield，NJ)也称为乳香，是一种印度部分地区干性森林中发现的乳香树的油-树胶脂提取物。其油-树胶脂芳香透明，颜色为带褐色的黄色。提取物的主要成分是三种三萜酸(triperpene acids)，□□，和□-乳香酸，其中，已知□-乳香酸是乳香具有抗肿瘤和抗关节炎活性的原因。从燕麦(Avena sativa)中分离的燕麦油提取物(Dragoco公司，Totowa，NJ)已经用于抗刺激和抗氧化。在37℃、5％CO2条件下，用或不用测试样品处理巨噬细胞培养物24小时，然后形成亚硝酸盐，用Griess分析测定稳定的一氧化氮最终产物。结果表示为与刺激的对照培养物相比，炎症介质产生的抑制百分比。
LPS刺激RAW 264鼠巨噬细胞
| 试验物质(浓度) | 一氧化氮释放抑制百分比(％) | 物理溶解度 |
| 赛普康姆(200ug/ml) | 10.58±0.7 | |
| 豨莶(2ug/ml) | 20.2±1.7 | 水溶性 |
| 豨莶(2ug/ml)+赛普康姆(200ug/ml) | 53.9±0.8* | |
| 苏木(20ug/ml) | 25.9±5.2 | 水溶性 |
| 苏木(20ug/ml)+赛普康姆(200ug/ml) | 66.8±1.3* | |
| 野甘菊(80ug/ml) | 36.0±1.0 | 水溶性/油溶性 |
| 野甘菊(80ug/ml)+赛普康姆(200ug/ml) | 55.63±1.9* | |
| 燕麦油提取物(50ug/ml) | 8.3±3.6 | 油溶性 |
| 燕麦油提取物(50ug/ml)+赛普康姆(200ug/ml) | 12.5±0.6 | |
| 乳香油提取物(50ug/ml) | 8.7±3.1 | 油溶性 |
| 乳香油提取物(50ug/ml)+赛普康姆(200ug/ml) | 17.55±0.6 |
*采用配对students t-检验，与单独使用化合物/提取物相比，P＜0.05
发现赛普康姆协同提高了水溶性提取物(豨莶和苏木)，部分水溶性/部分油溶性提取物(野甘菊)的抗炎活性，但没有协同提高油溶性提取物(燕麦油提取物、乳香油提取物)的抗炎活性。这些结果表明，赛普康姆能增强水溶性提取物和部分水溶性/部分油溶性提取物的活性。
实施例3
在四位成年白人妇女中进行研究，其皮肤类型在Fitzpatrick量表中为1-3型。试验期间在指定研究区域不允许使用乳液/产品。
调理期间使志愿者对象的皮肤干燥。要求使用对象在试验前7天遵循皮肤干燥方案。这包括每天2次用Ivory香皂清洗双腿(从膝盖以下)。整个试验期间持续该方案。
研究中，施加固定量的产品之前和施加后4小时进行评价。仅在第1天和第3天，在施加产品之前用刮除法在腿上各部位诱导刺激，如上所述进行测量。对两种产品进行测试；一种产品包含由1.0％赛普康姆、0.01％橄榄叶和0.5％Coviox T90构成的组合物(“活性”产品)，另一种产品是相同配制的安慰剂产品(“安慰剂”)，仅含有0.01％橄榄叶作为抗炎活性剂。
评估包括评价皮肤发红，用漫反射分光光谱分析(DRS)定量检测氧合血红蛋白的吸光度。
在干燥皮肤上每次处理后4小时皮肤发红的变化百分比
| 第1天 | 第2天 | 第3天 | 第4天 | |
| 活性剂 | 24.65％ | -37.81％ | -22.52％ | -27.13％ |
| SE | 17.53％ | 8.35％ | 10.04％ | 9.48％ |
| 安慰剂 | 31.74％ | -12.68％ | 4.86％ | 6.31％ |
| SE | 27.12％ | 12.28％ | 23.59％ | 22.19％ |
在干燥、刺激过的皮肤上每次处理后4小时皮肤发红的变化百分比
| 第1天 | 第2天 | 第3天 | 第4天 | |
| 活性剂 | 7.67％ | -39.69％ | -31.78％ | -1.13％ |
| SE | 7.19％ | 11.59％ | 9.79％ | 13.37％ |
| 安慰剂 | 15.88％ | -3.86％ | -1.96％ | -5.80％ |
| SE | 23.97％ | 26.25％ | 11.39％ | 11.43％ |
实施例4
将具有有益协同作用的各成分混合物掺入各种类型的产品中。这些产品包括但不限于：乳剂、表面活性剂、无水、片剂/粉末和聚合物系统。每种系统类型的例子，测定了各成分范围以及协同组分的上下限如下所示。
实施例4A-4F所述产品通过以下方法制备：
含油和水系统的生产说明：
1)组合水相成分，混合和加热直到均匀
2)组合油相成分，混合和加热直到均匀
3)两相处于相同温度时，将油相加到水相中，混合
4)混合直到均一，需要时匀浆化
5)冷却后加入防腐剂和芳香剂
无水系统的生产说明：
1)将所有成分加入主要反应罐中
2)加热混合直到相均一
3)倒入模具或包装，使冷却
Claims (17)
1.一种组合物，其包含：质量百分比10-90％的(a)抗炎剂，选自橄榄叶提取物、豨莶草、苏木、野甘菊以及其中两种或多种的组合，所述豨莶草是一种水性提取物，所述苏木是一种水性提取物，所述野甘菊是一种部分水溶性/部分油溶性提取物；和质量百分比90-10％的(b)抗炎剂，其包含至少一种椰油基氨基酸钠和至少两种或多种天冬氨酸盐。
2.如权利要求1所述的组合物，其特征在于，所述抗炎剂(a)包括橄榄叶提取物。
3.如权利要求1所述的组合物，其特征在于，所述抗炎剂(b)包含椰油基氨基酸钠、天冬氨酸镁和天冬氨酸钾的组合。
4.如权利要求1所述的组合物，其特征在于，所述组合物包含质量百分比20-80％的抗炎剂(a)和质量百分比80-20％的抗炎剂(b)。
5.如权利要求1所述的组合物，其特征在于，所述组合物包含质量百分比40-60％的抗炎剂(a)和质量百分比60-40％的抗炎剂(b)。
6.如权利要求1所述的组合物，所述组合物还包含至少一种额外的抗炎剂。
7.如权利要求6所述的组合物，其特征在于，所述至少一种额外的抗炎剂是选自抗坏血酸、生育酚和生育三烯酚的维生素。
8.如权利要求7所述的组合物，其特征在于，所述至少一种额外的抗炎剂包括生育酚。
9.一种组合物，其包含：质量百分比10-90％的(a)抗炎剂，选自橄榄叶提取物、豨莶草和苏木，所述豨莶草是一种水性提取物，所述苏木是一种水性提取物；和质量百分比90-10％的(b)抗炎剂，其包含椰油基氨基酸钠、天冬氨酸镁、天冬氨酸钾的组合。
10.如权利要求9所述的组合物，其特征在于，所述抗炎剂(a)包括橄榄叶提取物。
11.如权利要求10所述的组合物，其特征在于，所述组合物还包含一种或多种生育酚。
12.一种包含如权利要求1所述组合物的个人护理产品。
13.如权利要求12所述的个人护理产品，其特征在于，所述产品包含质量百分比0.02-1％的组合物。
14.如权利要求13所述的个人护理产品，其特征在于，所述产品包含质量百分比0.02-0.1％的组合物。
15.如权利要求14所述的个人护理产品，所述产品还包含生育酚。
16.一种包含如权利要求9所述组合物的个人护理产品。
17.如权利要求12所述的个人护理产品，所述产品还含有生育酚。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/216,441 | 2005-08-31 | ||
| US11/216,441 US8697152B2 (en) | 2005-08-31 | 2005-08-31 | Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract |
| PCT/US2005/034398 WO2007027187A1 (en) | 2005-08-31 | 2005-09-23 | Anti-inflammatory compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101291650A CN101291650A (zh) | 2008-10-22 |
| CN101291650B true CN101291650B (zh) | 2012-06-27 |
Family
ID=37804508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800518433A Active CN101291650B (zh) | 2005-08-31 | 2005-09-23 | 抗炎组合物及其使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8697152B2 (zh) |
| EP (1) | EP1933805A4 (zh) |
| JP (1) | JP5284093B2 (zh) |
| CN (1) | CN101291650B (zh) |
| AU (1) | AU2005335943B2 (zh) |
| BR (1) | BRPI0520503A2 (zh) |
| CA (1) | CA2620429A1 (zh) |
| RU (1) | RU2401120C2 (zh) |
| WO (1) | WO2007027187A1 (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8758838B2 (en) * | 2005-08-31 | 2014-06-24 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and methods of use |
| US8697152B2 (en) | 2005-08-31 | 2014-04-15 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract |
| JP5165299B2 (ja) * | 2007-07-20 | 2013-03-21 | ポーラ化成工業株式会社 | 皮膚外用剤 |
| US9168207B2 (en) * | 2010-08-19 | 2015-10-27 | Johnson & Johnson Consumer Inc. | Compositions comprising Paulownia tomentosa wood extracts and uses thereof |
| DK2667877T3 (en) * | 2011-01-26 | 2018-06-14 | Allergan Inc | ANDROGEN COMPOSITION FOR TREATMENT OF Ophthalmic condition |
| CN106074677B (zh) * | 2016-08-05 | 2020-12-22 | 山东大学 | 一种防治皮肤病变老化的中药组合物及其应用 |
| BR102016019121A2 (pt) * | 2016-08-17 | 2018-03-06 | Natura Cosméticos S.A. | Composição cosmética antissinais, uso da composição, método de tratamento antissinais e método para preenchimento de rugas da região dos lábios |
| BR102016019120A2 (pt) * | 2016-08-17 | 2018-03-06 | Natura Cosméticos S.A. | Composição cosmética antissinais, uso da composição, método de tratamento antissinais e método de redução de rugas |
| JPWO2019017355A1 (ja) * | 2017-07-18 | 2020-05-28 | 株式会社 資生堂 | 間葉系幹細胞誘引剤 |
| GB202117863D0 (en) * | 2021-12-10 | 2022-01-26 | Givaudan Sa | Cosmetic Ingredient |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2507477A1 (fr) | 1981-06-12 | 1982-12-17 | Roussel Uclaf | Nouveau procede de preparation d'un extrait de feuilles d'olea europea riche en oleuropeine, produits obtenus, application a titre de medicaments et compositions les renfermant |
| JPS5823612A (ja) | 1981-08-04 | 1983-02-12 | Osaka Chem Lab | 生薬成分含有化粧料組成物 |
| JPS60260513A (ja) * | 1984-06-08 | 1985-12-23 | Lion Corp | パツプ剤 |
| SE453724B (sv) | 1985-04-18 | 1988-02-29 | Nobel Consumer Goods Ab | Hudvardsmedel |
| AU618517B2 (en) | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
| US5922701A (en) | 1992-05-01 | 1999-07-13 | University Of Utah Research Foundation | Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue |
| JPH06172152A (ja) | 1992-12-04 | 1994-06-21 | Sunstar Inc | にきび予防化粧料組成物 |
| JP3769036B2 (ja) * | 1994-08-01 | 2006-04-19 | ポーラ化成工業株式会社 | 人体過剰対応抑制剤 |
| JPH09157172A (ja) | 1995-12-13 | 1997-06-17 | Lion Corp | 皮膚外用剤及び湿疹薬 |
| FR2760362B1 (fr) | 1997-03-10 | 2000-08-11 | Vitasterol | Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles |
| FR2765109B1 (fr) | 1997-06-25 | 2001-02-09 | Seppic Sa | Composition comprenant un lipoaminoacide et les constituants d'un extrait de plantes riches en tanins et utilisation en cosmetique |
| IT1298283B1 (it) | 1998-02-19 | 1999-12-20 | B & T S R L | Uso dell'estratto delle foglie di olea europea come antiradicalico |
| JPH11343235A (ja) * | 1998-04-02 | 1999-12-14 | Ajinomoto Co Inc | アミノ酸誘導体および炎症因子活性化抑制剤 |
| JP3929613B2 (ja) | 1998-08-20 | 2007-06-13 | 株式会社カネボウ化粧品 | 化粧料 |
| EP1010708B1 (fr) | 1998-12-18 | 2004-03-31 | Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C. | Utilisation en cosmétique d'un latex inverse stable aux électrolytes |
| JP2000247829A (ja) | 1999-02-24 | 2000-09-12 | Mikimoto Pharmaceut Co Ltd | 化粧料、医薬部外品、医薬品、食品 |
| US6440432B1 (en) | 1999-03-18 | 2002-08-27 | Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. | Skin cosmetic compositions containing dextran or maltodextrin and a weak carboxylic acid |
| FR2790977B1 (fr) * | 1999-03-19 | 2003-09-12 | Seppic Sa | Nouvelles emulsions eau-dans-huile stables contenant un emulsionnant a base d'oleyl- et/ou d'isostearyl-glycoside |
| GB9908976D0 (en) * | 1999-04-21 | 1999-06-16 | Breed Automotive Tech | A seat belt retractor |
| JP2001002550A (ja) | 1999-06-18 | 2001-01-09 | Ichimaru Pharcos Co Ltd | オリーブ葉抽出物、皮膚外用剤又は浴用剤への応用 |
| US6762158B2 (en) | 1999-07-01 | 2004-07-13 | Johnson & Johnson Consumer Companies, Inc. | Personal care compositions comprising liquid ester mixtures |
| FR2808191B1 (fr) | 2000-04-28 | 2004-03-05 | Oreal | Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations |
| US6440465B1 (en) * | 2000-05-01 | 2002-08-27 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
| US20050003023A1 (en) | 2002-06-28 | 2005-01-06 | Meisner Lorraine Faxon | Topical composition for the treatment of psoriasis and related skin disorders |
| JP4693012B2 (ja) | 2000-06-29 | 2011-06-01 | 一丸ファルコス株式会社 | 光毒性抑制剤 |
| FR2818149A1 (fr) | 2000-12-15 | 2002-06-21 | Oreal | Composition, notamment cosmetique, comprenant la 7-hydroxy dhea et/ou 7-ceto dhea et au moins un inhibiteur de 5 alpha-reductase |
| US20030077343A1 (en) | 2001-03-16 | 2003-04-24 | Martin Katharine M. | Composition containing feverfew extract and use thereof |
| JP4583655B2 (ja) | 2001-05-08 | 2010-11-17 | 株式会社ディーエイチシー | 抗アレルギー皮膚外用組成物 |
| FR2835252B1 (fr) * | 2002-01-25 | 2005-08-05 | Seppic Sa | Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaicir la peau |
| US20030224028A1 (en) | 2002-05-13 | 2003-12-04 | Societe L'oreal S.A. | Metal complexes for promoting skin desquamation and/or stimulating epidermal renewal |
| FR2848116B1 (fr) | 2002-12-10 | 2007-01-05 | Nuxe Lab | Composition cosmetique comprenant un inhibiteur des metallo-proteinases et un lipopeptide. |
| FR2851460B1 (fr) | 2003-02-21 | 2007-05-11 | Seppic Sa | Utilisation de n-lauroyl aminoacides comme actif cosmetique et pharmaceutique amincissant |
| US20050129759A1 (en) * | 2003-12-16 | 2005-06-16 | Milan Sojka | Sustained release compositions and controlled delivery method |
| US20070154532A1 (en) | 2003-12-30 | 2007-07-05 | Med Care S.R.L. | Compositions comprising vitamins and/or derivatives thereof stablished with olea europea extract and/or ionene polymers |
| US7691399B2 (en) | 2004-02-03 | 2010-04-06 | Alberto Culver Company | Cosmetic compositions with long lasting skin moisturizing properties |
| US20050186269A1 (en) | 2004-02-25 | 2005-08-25 | Udell Ronald G. | Stabilized feverfew formulations |
| US8697152B2 (en) | 2005-08-31 | 2014-04-15 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract |
| US8758838B2 (en) | 2005-08-31 | 2014-06-24 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and methods of use |
| JP4893148B2 (ja) | 2006-08-09 | 2012-03-07 | 株式会社日立製作所 | 形状簡略化装置及びそれに用いられるプログラム |
-
2005
- 2005-08-31 US US11/216,441 patent/US8697152B2/en active Active
- 2005-09-23 JP JP2008528998A patent/JP5284093B2/ja not_active Expired - Fee Related
- 2005-09-23 EP EP05801043A patent/EP1933805A4/en not_active Withdrawn
- 2005-09-23 AU AU2005335943A patent/AU2005335943B2/en not_active Ceased
- 2005-09-23 CN CN2005800518433A patent/CN101291650B/zh active Active
- 2005-09-23 BR BRPI0520503-4A patent/BRPI0520503A2/pt not_active IP Right Cessation
- 2005-09-23 WO PCT/US2005/034398 patent/WO2007027187A1/en active Application Filing
- 2005-09-23 RU RU2008112131/15A patent/RU2401120C2/ru not_active IP Right Cessation
- 2005-09-23 CA CA002620429A patent/CA2620429A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2401120C2 (ru) | 2010-10-10 |
| US8697152B2 (en) | 2014-04-15 |
| US20070048397A1 (en) | 2007-03-01 |
| EP1933805A1 (en) | 2008-06-25 |
| JP5284093B2 (ja) | 2013-09-11 |
| CN101291650A (zh) | 2008-10-22 |
| JP2009506111A (ja) | 2009-02-12 |
| AU2005335943A1 (en) | 2007-03-08 |
| RU2008112131A (ru) | 2009-10-10 |
| CA2620429A1 (en) | 2007-03-08 |
| BRPI0520503A2 (pt) | 2009-05-12 |
| WO2007027187A1 (en) | 2007-03-08 |
| EP1933805A4 (en) | 2012-12-26 |
| AU2005335943B2 (en) | 2012-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101291650B (zh) | 抗炎组合物及其使用方法 | |
| CN101287480B (zh) | 抗炎组合物及其使用方法 | |
| US7674488B2 (en) | External composition comprising an aqueous extract of red vine leaves and an anti-inflammatory agent | |
| Nabavi et al. | Biological activities of freshwater algae, Spirogyra singularis Nordstedt | |
| CN101496782A (zh) | 一种含有中药成分的足浴液 | |
| Nunes et al. | Potential therapeutic of olive oil industry by‐products in skin health: a review | |
| CN110025538B (zh) | 一种改善皮肤痤疮、炎症的组合物及其应用 | |
| CN112294709A (zh) | 一种具有抗炎、抗氧化功效的免洗凝胶消毒液及其制备方法 | |
| Saremi et al. | The Combined Effects of Nano-Zinc, Nano-Albumin and Honey in Healing Wounds Caused by Third-Degree Burn in Male Mice | |
| Reshmi et al. | Medicinal Properties of Njavara Rice (Oryza Sativa L.) cv. | |
| KR20030092519A (ko) | 알레르기성 피부질환의 개선 또는 예방용 조성물 | |
| KR102637448B1 (ko) | 아토피 피부 개선 화장료, 이의 제조방법 및 이를 포함하는 화장품 | |
| CN107638336A (zh) | 一种祛痘美白护肤品及其制备方法 | |
| WO2017149331A1 (en) | N-bromotaurine solutions and emulsions against abnormal cells | |
| KR20160069610A (ko) | 탈모 방지, 발모 촉진, 피부 노화 방지, 피부 재생, 항염 및 항균 효과 등을 가지는 홍삼 및 천연식물 추출물의 제조방법, 및 그를 포함하는 조성물 | |
| Nieman | To B or not to B? The B vitamins and their influence on the body's largest organ | |
| WO2011161529A2 (en) | Nutritional supplement | |
| CN111297768A (zh) | 一种抗氧化活性组合物、抗氧化面膜及其制备和应用 | |
| KR20160094907A (ko) | 탈모 방지, 발모 촉진, 피부 노화 방지, 피부 재생, 항염 및 항균 효과 등을 가지는 홍삼 및 천연식물 추출물의 제조방법, 및 그를 포함하는 조성물 | |
| CN102138884A (zh) | 一种应用于洗护产品的组合物及洗护产品 | |
| Majeed et al. | Targeting Optimal Nutrient Absorption with Phytonutrients | |
| DE102006030031A1 (de) | Artikel gegen Candida-Infektionen | |
| Deutsch | rosehip seed oil | |
| DE102006030035A1 (de) | Topisch anzuwendendes Produkt zur Vorbeugung und Behandlung von Seborrhoischer Dermatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220428 Address after: new jersey Patentee after: JOHNSON & JOHNSON CONSUMER COMPANIES, Inc. Address before: Delaware Patentee before: Johnson & Johnson consumer Co.,Ltd. Effective date of registration: 20220428 Address after: Delaware Patentee after: Johnson & Johnson consumer Co.,Ltd. Address before: new jersey Patentee before: JOHNSON & JOHNSON CONSUMER COMPANIES, Inc. |